(Q35596955)

9 August 2017

title

Rare occurrence of DNMT3A mutations in myelodysplastic syndromes (English)

1 reference

9 August 2017

Felicitas Thol

1

1 reference

9 August 2017

Claudia Winschel

2

1 reference

9 August 2017

Andrea Lüdeking

3

1 reference

9 August 2017

Haiyang Yun

4

1 reference

9 August 2017

Inna Friesen

5

1 reference

9 August 2017

Frederik Damm

6

1 reference

9 August 2017

Katharina Wagner

7

1 reference

9 August 2017

Jürgen Krauter

8

1 reference

9 August 2017

Michael Heuser

9

1 reference

9 August 2017

Arnold Ganser

10

1 reference

9 August 2017

publication date

31 August 2011

1 reference

9 August 2017

1 reference

9 August 2017

volume

96

1 reference

9 August 2017

issue

12

1 reference

9 August 2017

page(s)

1870-1873

1 reference

Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3232272

Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3232272

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3232272

Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3232272

DNMT3A Mutations in Acute Myeloid Leukemia

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3232272

IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3232272

Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3232272

Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3232272

DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3232272

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3232272

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3232272

Oral iron chelators: prospects for future development.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3232272

DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3232272

A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes

26 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21880636

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Treatment of patients with low-risk myelodysplastic syndromes using a combination of all- trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21880636

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21880636

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3324/HAEMATOL.2011.045559

1 reference

9 August 2017

1 reference

9 August 2017

1 reference